#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4304	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2793	448.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1935	1935	C	617	C	551	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6836	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4205	487.0	0	.	n	.	0	T695C	SNP	695	695	T	1231	1231	C	515	C,T,A	456,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6836	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4205	487.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1873	1873	A	608	A	566	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6836	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4205	487.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2507	2507	C	635	C,A	573,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6836	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4205	487.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3133	3133	T	595	T,G	534,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6836	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4205	487.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2581	2581	A	661	A,T	603,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	648	folP	852	852	100.0	folP.l15.c4.ctg.1	2015	96.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1236	1238	AGC	136;136;137	A;G;C	119;123;126	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1438	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4166	103.4	0	.	p	.	0	V857A	NONSYN	2569	2571	GTG	3254	3256	GCG	134;133;133	G;C,T;G	120;118,1;117	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1438	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4166	103.4	1	SNP	p	S91F	0	.	.	271	273	TCC	956	958	TCC	116;116;117	T;C;C	101;102;103	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1438	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4166	103.4	1	SNP	p	D95G	0	.	.	283	285	GAC	968	970	GAC	118;117;117	G,C;A;C	103,1;106;105	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1438	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4166	103.4	1	SNP	p	D95N	0	.	.	283	285	GAC	968	970	GAC	118;117;117	G,C;A;C	103,1;106;105	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	644	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1743	110.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	692	694	ACC	154;153;152	A,C;C;C,T	140,1;142;140,1	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	644	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1743	110.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	707	709	CAC	160;160;160	C;A,C;C	139;142,1;143	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	644	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1743	110.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	890	892	CAC	173;174;176	C;A,C;C	154;156,1;153	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	644	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1743	110.6	1	SNP	p	G45D	0	.	.	133	135	GGC	710	712	GGC	158;157;157	G;G,T;C,G	144;139,1;140,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	436	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1442	90.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1544	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3396	136.1	1	SNP	p	D86N	0	.	.	256	258	GAC	806	808	GAC	163;163;163	G;A,C;C	151;148,1;150	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1544	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3396	136.1	1	SNP	p	S87R	0	.	.	259	261	AGT	809	811	AGT	164;165;165	A,C;G;T	142,1;152;150	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1544	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3396	136.1	1	SNP	p	S87I	0	.	.	259	261	AGT	809	811	AGT	164;165;165	A,C;G;T	142,1;152;150	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1544	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3396	136.1	1	SNP	p	S87W	0	.	.	259	261	AGT	809	811	AGT	164;165;165	A,C;G;T	142,1;152;150	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1544	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3396	136.1	1	SNP	p	S88P	0	.	.	262	264	TCC	812	814	TCC	165;166;166	T;C;C	147;146;151	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1246	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3224	115.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1849	1851	GGC	149;148;147	G;G;C	137;138;137	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1497	1499	GCA	172;170;170	G,C;C;A,C	155,1;151;149,2	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1500	1502	ATC	169;169;170	A,C;T;C,G	148,1;149;150,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1512	1514	GTG	170;170;171	G,A;T,C;G,C	157,1;152,2;152,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1512	1514	GTG	170;170;171	G,A;T,C;G,C	157,1;152,2;152,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2016	2018	ACC	124;125;126	A;C;C	104;112;112	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2070	2072	GCG	129;129;130	G,T,A;C;G	115,1,1;104;110	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2070	2072	GCG	129;129;130	G,T,A;C;G	115,1,1;104;110	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2193	2195	GGC	130;130;130	G,C,A;G,C;C	112,2,1;114,1;120	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2202	2204	GGC	135;135;135	G;G;C,G	117;122;121,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1172	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2870	122.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2220	2222	CCG	138;140;140	C,G;C;G,A	116,1;125;118,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1610	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3780	127.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1957	1959	CTG	150;148;146	C;T;G	126;129;128	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	716	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2357	91.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	870	870	C	116	C	105	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1073	1075	AAT	6;6;6	A;A;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1076	1078	AAT	7;6;6	A;A;T	6;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1100	1102	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1123	1125	GTA	5;5;5	G;T;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	.	INDELS	709	710	AA	1133	1137	GTGAG	4;4;4;4;4	G;T;G;A;G	4;4;4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	D238G	NONSYN	712	714	GAT	1139	1141	GGT	4;4;4	G;G;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1178	1180	GTA	4;4;4	G;T;A	4;4;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	S271T	NONSYN	811	813	TCG	1238	1240	ACT	3;3;3	A;C;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	1244	1246	GAT	3;3;3	G;A;T	2;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	D276N	NONSYN	826	828	GAT	1253	1255	AAC	3;3;3	A;A;C	2;3;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1345	19.7	0	.	p	.	0	N277H	NONSYN	829	831	AAC	1256	1258	CAC	3;3;3	C;A;C	3;3;3	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	0	.	p	.	0	I45V	NONSYN	133	135	ATT	655	657	GTT	177;177;176	G;T;T	159;157;156	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	0	.	p	.	0	I75V	NONSYN	223	225	ATT	745	747	GTT	184;184;184	G;T,G;T	167;158,1;165	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	0	.	p	.	0	S89T	NONSYN	265	267	AGC	787	789	ACC	191;193;193	A;C;C,T	174;174;174,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	0	.	p	.	0	I98V	NONSYN	292	294	ATC	814	816	GTC	189;189;189	G;T,A;C	172;169,1;173	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	922	924	GAT	173;174;175	G;A;T	164;158;164	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	0	.	p	.	0	M254V	NONSYN	760	762	ATG	1282	1284	GTG	143;143;143	G,A;T;G,T	133,1;135;133,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	1	SNP	p	G120K	1	.	.	358	360	AAG	880	882	AAG	193;191;191	A;A;G,A	173;172;172,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	1	SNP	p	A121N	1	.	.	361	363	AAC	883	885	AAC	191;189;189	A,G;A;C	168,1;173;171	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	816	porB1b	1038	1038	99.33	porB1b.l15.c30.ctg.1	2091	116.3	1	SNP	p	N121D	0	.	.	361	363	AAC	883	885	AAC	191;189;189	A,G;A;C	168,1;173;171	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2478	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5335	139.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2288	2290	AAT	133;133;134	A;A;T	122;121;122	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	412	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1363	90.2	1	SNP	p	V57M	1	.	.	169	171	ATG	662	664	ATG	162;162;160	A;T,G;G	148;145,1;149	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
